Hikma Pharmaceuticals PLC (HKMPF PINK) stock market data APIs
$19.1165
0(0%)
as of May 7, 2026
Try our APIs with
free plan!
Hikma Pharmaceuticals PLC Financial Data Overview
Price chart is built with
Anychart
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Prev. Close
19.1165
Open
19.1165
High
19.1165
Low
19.1165
52 wk Range
15.9448-27.5468
Market Cap
3 866 M
P/E Ratio
9.9448
Shares Outstanding
215 M
Revenue
3 349 M
EPS
0.5345
Dividends (Yield)
0.0437
Beta
0.643
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Hikma Pharmaceuticals PLC data using free add-ons & libraries
Get Hikma Pharmaceuticals PLC Fundamental Data
Hikma Pharmaceuticals PLC Fundamental data includes:
- Net Revenue: 3 349 M
- EBITDA: 842 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Hikma Pharmaceuticals PLC Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2021-06-30
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Hikma Pharmaceuticals PLC News
New
Pfizer (PFE) Reaches Settlement to Extend VYNDAMAX Patent Protection Until 2031
Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals...
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
NEW YORK, April 28, 2026--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals a...
How The Hikma Pharmaceuticals (LSE:HIK) Narrative Is Shifting With Reset Valuations And Buybacks
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The fair value price target for Hikma Pharmaceuticals has...
How The Investment Story On Hikma Pharmaceuticals (LSE:HIK) Is Shifting With New Targets And News
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Hikma Pharmaceuticals’ fa...
Get Hikma Pharmaceuticals PLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
